Lentiviral GLP-1 Gene Therapy Elicits Developmental Stage-Dependent β-Cell Regeneration in Diabetic Rats
Background
Pancreatic β-cell dysfunction and loss are central to Type 2 Diabetes (T2DM). While the neonatal pancreas exhibits high plasticity for β-cell formation, adult pancreases have limited regenerative potential, hindering effective T2DM reversal. Glucagon-like peptide-1 (GLP-1) is known to promote β-cell survival and proliferation, but its specific effects on regeneration across different developmental stages, particularly regarding progenitor and ductal cell differentiation, remain underexplored. This gap limits strategies for age-specific diabetes therapies.
Study Design
Researchers developed a third-generation HIV-based lentiviral vector, LentiGLP-1, encoding native GLP-1 under a CMV promoter. This vector's ability to modulate β-cell differentiation and proliferation was assessed in neonatal and adult diabetic rat models. Type 2 Diabetes was induced in neonatal rats using low-dose streptozotocin (STZ). Adult rats received a high-fat diet combined with low-dose STZ. The primary endpoints included assessment of β-cell differentiation from ductal and progenitor cells, and overall β-cell proliferation.
Results
LentiGLP-1 administration markedly promoted differentiation of ductal and progenitor cells into insulin-producing β-cells in neonatal rats. This was accompanied by enhanced β-cell proliferation, demonstrating effective engagement of developmental plasticity.
In adult rats, LentiGLP-1 partially restored β-cell populations through activation of residual progenitors and stimulation of replication in existing β-cells, leading to improved glycemic control and insulin sensitivity. Notably, acinar cells did not contribute to β-cell generation in either neonatal or adult models. These findings indicate that GLP-1 exerts developmentally regulated effects, facilitating neogenesis in neonates and partially restoring regenerative capacity in adults.
Key Findings
- Lentiviral GLP-1 gene therapy markedly promoted β-cell differentiation from ductal and progenitor cells in neonatal diabetic rats.
- LentiGLP-1 enhanced β-cell proliferation in neonatal diabetic rats, engaging developmental plasticity.
- LentiGLP-1 partially restored β-cell populations in adult diabetic rats by activating progenitors and stimulating existing β-cells.
- LentiGLP-1 improved glycemic control and insulin sensitivity in adult diabetic rats.
- Acinar cells did not contribute to β-cell generation in either neonatal or adult models.
Why It Matters
This research highlights the potential of long-term GLP-1 expression via gene therapy as a strategy to restore β-cell mass, offering a novel approach for Type 2 Diabetes treatment. The finding that GLP-1 effects are developmentally regulated suggests that age-specific therapeutic protocols could be optimized, potentially leveraging the higher plasticity of younger individuals for more robust β-cell regeneration. For future clinical translation, this work provides insight into how GLP-1 could be delivered for sustained therapeutic benefit, moving beyond daily injections towards a more durable solution for glycemic control and insulin sensitivity.
glp-1
gene-therapy
beta-cell-regeneration
diabetes
t2dm
preclinical-animal